An observational study in COVID-19, sponsored by Weprom. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-08.
Sponsored by Weprom · Observational
A coronavirus pandemic began on 12/31/2020 with the first Chinese patient. As of 3/16/2020, the epidemic affects more than 100 countries with 169,000 official infections and 6,500 deaths. This virus causes a pathology ranging from simple flu symptoms in 80% of cases to acute respiratory distress syndromes requiring resuscitation in 5% of cases and a death rate of 1.4 to 4% of cases.
The arrival in France on 02/25/2020 with an exponential development of the infection (more than 5,000 cases on 03/15/2020) was accompanied by an unprecedented number of calls to the French emergency service call number (15) of worried patients with overload and sometimes saturation of the service that can impact calls and the care of patients really recovering from an emergency.
We previously developed a Moovcare® web application which showed a 7 months survival benefit by early detection of relapsed lung cancer based on the reporting of patient symptoms analyzed by a validated algorithm in 300 patients and 1 trial randomized. Another application for detecting and monitoring chemo-induced febrile aplasia appears to show a reduction in the number of hospitalizations for sepsis. Finally, Smokecheck, a self-assessment application for symptoms by smokers, has shown that it improves the detection of symptomatic operable bronchial cancers (9 to 24%, p = 0.04).
The web application https://www.maladiecoronavirus.fr/ was developed with a group of physicians from the Institut Pasteur, Hospitals group of Paris, Hospitals of Lille and Rennes and the ILC Jean Bernard in Le Mans. It makes it possible to guide symptomatic patients and patients who wishing to know what to do (call their general practitioner, teleconsultation, or call emergency service) based on symptoms and predictive factors of severity.
Following the availability of this new tool, we want to assess the impact of the application on the number and relevance of calls to emergency service.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 12,000,000 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Weprom is the lead sponsor of 21 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All users of the https://www.maladiecoronavirus.fr/ application over the age of 18
Exclusion Criteria:
questionnaire of comorbidity and symptomes completed by the user on his smartphone
Device: Web application users
questionnaire of comorbidity and symptoms completed by the patient on his smartphone
To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/
Number of calls to Emergency service after the launch of web application comparded to the days before
Time frame: 12 days
To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/
Number of relevants calls to Emergency service after the launch of web application comparded to the days before
Time frame: 12 days
To assess the evolution over time of the COVID 19 epidemic
the symptoms collected by the application
Time frame: 3 months
To assess the evolution over space of the COVID 19 epidemic
the symptoms collected by the application according to ZIP code
Time frame: 3 months
To assess symptoms
Descriptive analysis of symptoms collected by web-application
Time frame: 3 months
To assess the users population
Descriptive analysis of data collected by web-application
Time frame: 3 months
Plan to share: No
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weprom